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Summary
Background—Swaziland has the highest national HIV prevalence worldwide. The Swaziland 
HIV Incidence Measurement Survey (SHIMS) provides the first national HIV incidence estimate 
based on prospectively observed HIV seroconversions.
Methods—A two-stage survey sampling design was used to select a nationally representative 
sample of men and women aged 18–49 years from 14 891 households in 575 enumeration areas in 
Swaziland, who underwent household-based counselling and rapid HIV testing during 2011. All 
individuals aged 18–49 years who resided or had slept in the household the night before and were 
willing to undergo home-based HIV testing, answer demographic and behavioural questions in 
English or siSwati, and provide written informed consent were eligible for the study. We 
performed rapid HIV testing and assessed sociodemographic and behavioural characteristics with 
use of a questionnaire at baseline and, for HIV-seronegative individuals, 6 months later. We 
calculated HIV incidence with Poisson regression modelling as events per person-years × 100, and 
we assessed covariables as predictors with Cox proportional hazards modelling. Survey weighting 
was applied and all models used survey sampling methods.
Findings—Between Dec 10, 2010, and June 25, 2011, 11 897 HIV-seronegative adults were 
enrolled in SHIMS and 11 232 (94%) were re-tested. Of these, 145 HIV seroconversions were 
observed, resulting in a weighted HIV incidence of 2·4% (95% CI 2·1–2·8). Incidence was nearly 
twice as high in women (3·1%; 95% CI 2·6–3·7) as in men (1·7%; 1·3–2·1, p<0·0001). Among 
men, partner’s HIV-positive status (adjusted hazard ratio [aHR] 2·67, 1·06–6·82, p=0·040) or 
unknown serostatus (aHR 4·64, 2·32–9·27, p<0·0001) in the past 6 months predicted HIV 
seroconversion. Among women, significant predictors included not being married (aHR 2·90, 
1·44–5·84, p=0·0030), having a spouse who lives elsewhere (aHR 2·66, 1·29–5·45, p=0·0078), and 
having a partner in the past 6 months with unknown HIV status (aHR 2·87, 1·44–5·84, p=0·0030).
Interpretation—Swaziland has the highest national HIV incidence in the world. In high-
prevalence countries, population-based incidence measures and programmes that further expand 
HIV testing and support disclosure of HIV status are needed.
Funding—President’s Emergency Plan for AIDS Relief (PEPFAR) by the Centers for Disease 
Control and Prevention.
Justman et al. Page 2
Lancet HIV. Author manuscript; available in PMC 2017 February 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Introduction
Swaziland has the most severe HIV epidemic in the world, with a measured HIV prevalence 
of 26% among adults aged 15–49 years in 2006–07.1 To combat this epidemic, in 2009, the 
Government of the Kingdom of Swaziland (GKOS) initiated support for scale-up of national 
HIV prevention and treatment programmes, including a voluntary medical male 
circumcision campaign.2 The Swaziland HIV Incidence Measurement Survey (SHIMS) was 
designed to assess the effect of these programmes on HIV incidence by prospectively 
measuring HIV seroconversions in a household-based, nationally representative sample of 
adults before and after programme expansion.
The approach of “know your epidemic, know your response”3 is crucial to effective HIV 
programmes, and having accurate and detailed HIV incidence estimates is fundamental to 
this approach. Incidence estimates allow identification of groups at the highest risk of new 
infections and, when repeated, determine the effect of programmes over time. Although 
incidence estimates of large populations are often modelled from trends in HIV prevalence,4 
such modelled estimates provide little demographic detail. HIV incidence laboratory 
assays5,6 are intended for use in cross-sectional surveys but have yet to achieve optimum 
performance.7 HIV incidence estimates based on the gold standard of observed HIV 
seroconversions have not been available at a national level although they have been available 
from randomised clinical trials or observational cohorts restricted to subpopulations at 
increased risk of HIV.8,9 We report the national estimate, before programme expansion, of 
HIV incidence based on population-level, prospectively observed seroconversions.
Methods
Study design and participants
A two-stage sampling design was used to obtain a cross-sectional, nationally representative 
sample of adults aged 18–49 years in a survey of 14 891 households from 575 enumeration 
areas in Swaziland (figure 1), with household sample size calculations and other details as 
previously reported.10 Each selected household was approached by study personnel trained 
in Good Clinical Practice11 who asked responding heads of household to report the sex and 
age of all household members. All individuals aged 18–49 years who resided or had slept in 
the household the night before and were willing to undergo home-based HIV testing, answer 
demographic and behavioural questions in English or siSwati, and provide written informed 
consent were eligible for the study. We enrolled in the prospective HIV incidence cohort 
those HIV-seronegative individuals who consented to have a 6 month follow-up home-based 
HIV testing and counselling visit. The SHIMS protocol and consent forms were reviewed 
and approved by the GKOS Scientific and Ethics Committee and the institutional review 
boards at Columbia University Medical Center and the US Centers for Disease Control and 
Prevention.
Evidence before this study
Swaziland’s Demographic and Health Survey done in 2006–07 showed a severe 
generalised epidemic, with an HIV prevalence of 26% in 15–49 year olds. UNAIDS’ 
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modelled estimates of prevalence and incidence indicated a similarly severe epidemic. 
With a goal of reducing new HIV infections, Swaziland planned to scale up national 
treatment and prevention programmes. The Swaziland HIV Incidence Measurement 
Survey (SHIMS) was designed to assess HIV incidence before and after scale-up of these 
intervention programmes by measuring prospectively observed HIV seroconversion in a 
nationally representative adult cohort. A search of PubMed for studies published in 
English through to Nov 7, 2016, using the search terms “HIV incidence”, “longitudinal 
cohort”, and “nationally representative” confirmed no previous direct measurement of 
national HIV incidence using this method.
Added value of this study
This study reports the baseline results, before scale up of national interventions, of the 
first national HIV incidence measurement on the basis of prospectively observed 
seroconversion, the “gold standard” measure of the spread of infection. High retention 
rates, a rigorous HIV testing algorithm, and a large number of seroconverter cases permit 
an accurate and detailed description of HIV incidence in Swaziland, a country at the 
centre of the global HIV epidemic.
Implications of all the available evidence
As the global scale-up of antiretroviral treatment extends into its second decade, accurate 
and detailed knowledge of each country’s epidemic is increasingly crucial to implement 
an effective local HIV response.
Procedures
Study teams comprising one nurse and one or two counsellors did HIV counselling, 
venepuncture, and rapid HIV testing, provided condoms, and collected demographic, 
clinical, and behavioural information with questionnaires12 administered during face-to-face 
interviews in a private location in or just outside the home. HIV test results were given to 
participants during the household visit. All HIV-seronegative individuals enrolled in the HIV 
incidence cohort had a 6 month follow-up visit, with similar procedures, including 
verification of participant identity and repeat HIV testing. At the baseline and 6 month 
follow-up interviews, information was obtained about sexual behaviours in the past 6 
months and characteristics of the three most recent sexual partners. Current pregnancy status 
in women was based on self-report. All individuals who tested HIV seropositive at either the 
baseline or follow-up visit were counselled and referred to HIV care as per national 
guidelines.
Rapid HIV testing was done in the field on whole blood samples obtained by venepuncture, 
as previously described.10,13 Samples were initially tested with Determine HIV-1/2Ag/Ab 
Combo (Alere, Japan) and Determine-reactive samples were confirmed with Uni-Gold HIV 
Test (Trinity Biotech, Ireland), following Swaziland’s serial testing algorithm. All HIV-
seronegative samples from the baseline visit, but not the follow-up visit, had a nucleic acid 
amplification test (NAAT) with pools of ten samples to identify individuals with virological 
evidence of acute HIV infection.14,15 Individuals with NAAT-positive results had follow-up 
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visits within 6 months to confirm seroconversion and were subsequently censored from the 
incidence analyses.13
Statistical analysis
Probability of household selection within census enumeration areas of each of the four 
regions was designed to be proportional to population size and all household members were 
approached for selection. Corresponding design weights were then adjusted for non-
response, within cross classification of age group, region, urban or rural living area, and sex, 
and post-stratification weights were calculated to match these same characteristics of the 
2007 Swaziland census. Weights were scaled so that the weighted total matched the 
unweighted total number of participants. Proportions and 95% CIs were computed with 
survey sampling methods, weighted for sampling design,10,16 non-response, and post-
stratification, to achieve nationally representative findings.
Unless otherwise noted, all analyses were based on all those individuals who were enrolled 
in the incidence cohort and who completed a follow-up visit; similarly, unless otherwise 
indicated, for each variable, 1% of participants or less refused to answer the question, 
answered “I don’t know”, or had missing data, and these data were excluded. We used 
statistical methods for multistage surveys throughout, and all models were fitted with SAS, 
version 9.2. We used survey Poisson regression models to estimate seroincidence rates and 
CIs.
We analysed factors associated with the risk of seroconversion with survey proportional 
hazards, including number of sexual partners, marital status, condom use, knowledge of 
partner’s HIV status, pregnancy, and circumcision status. To avoid imposing an assumption 
of constant HIV risk, we used the Cox proportional hazards model, rather than the Poisson 
regression model, to assess associations of baseline covariates with HIV seroincidence.
We fitted all regression models separately for men and women. Variables were included in 
the multivariable models when the covariate had a p value lower than 0·1 in the univariable 
model. For explanatory variables expected to be consistent over a 6 month period, such as 
age, marital status, and HIV testing history, the analyses used data collected at baseline; for 
variables of sexual history, sexual activity in the past 6 months, pregnancy, and male 
circumcision status, the analysis used data collected at baseline and follow-up. To estimate 
the risk of HIV seroconversion for covariates of sexual behaviour, such as number of 
partners in the past 6 months, the analysis used data reported at follow-up, during the period 
of risk of HIV seroconversion. Population attributable risk was computed with the adjusted 
hazard ratio (aHR) to estimate the relative risk.
Role of the funding source
The funder participated in study design, data analysis, data interpretation, and writing of the 
report. The corresponding author had full access to all the data in the study and had final 
responsibility for the decision to submit for publication.
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Results
Between Dec 10, 2010, and June 25, 2011, study staff approached 14 891 selected 
households from the four administrative regions of Swaziland (figure 1). Among the 13 335 
occupied households (figure 2), the head of household for 12 571 (94%) households 
provided information about 54 655 household members, of whom 24 630 (45%) were 
eligible for inclusion in this study on the basis of age and residence. Of these, 18 177 (74%) 
adults agreed to participate in the survey and undergo HIV testing; survey participation rates 
were higher in women (11 044 [81%] of 13 582) than in men (7133 [64%] of 11 048). Of 
the 18 172 participants with available HIV test results, 5803 (32%) were HIV seropositive 
and 13 were NAAT positive, as previously reported.10,13 Among the remaining 12 369 
potentially eligible HIV-seronegative individuals, 11 897 (96%) enrolled in the cohort and, 
of these, 11 232 (94%) were successfully retained and retested for HIV at a 6 month follow-
up visit which occurred between Aug 23, 2011, and Feb 4, 2012; the mean duration of 
follow-up was 6·5 (IQR 6·0–6·7) months.
Survey-weighted estimates show the demographic and behavioural profile of the population 
of HIV-seronegative adults in Swaziland in 2011 (table 1). The mean age was 28·3 years 
(27·4 years in men; 29·3 years in women), with about half of participants aged between 20–
29 years. Most participants had completed either primary or secondary education, were 
living in rural areas, and were unemployed. About a third of the seronegative population 
reported no previous HIV testing.
Among those who reported ever having had sex, most reported at the follow-up visit having 
one sexual partner within the past 6 months and 967 (10%) of 9855 participants: 874 (18%) 
of 4788 men and 93 (2%) of 5067 women reported having two or more partners in the past 6 
months. Among individuals reporting one or more partners in the past 6 months, most 
reported all partners as HIV negative, 917 (12%) of 8048 reported one or more HIV-positive 
partner, and 920 (11%) of 8048 reported having any partner with unknown HIV status. 
Among individuals reporting one or more partners in the past 6 months, only 24 (<1%) of 
8048 reported anal sex, and most opted not to answer this question (data not shown). 
Potentially eligible HIV-seronegative adults who did not participate in the incidence cohort 
were less likely to be married (p=0·003), more likely to have two or more partners 
(p=0·002), and were less likely to have previously tested for HIV (p=0·015).
After applying survey weighting, 145 HIV seroconversions occurred during 6086 person-
years of observation, corresponding to an annualised population incidence estimate of 2·4 
per 100 person-years (95% CI 2·1–2·8). Incidence was nearly twice as high in women (3·1 
per 100 person-years, 95% CI 2·6–3·7) as in men (1·7 per 100 person-years, 95% CI 1·3–
2·1; p<0·0001) and patterns of incidence by demographic and behavioural characteristics 
varied by sex (table 2, figure 3).
HIV incidence in men peaked in those aged 30–34 years (3·1 per 100 person-years, 95% CI 
1·9–5·1). HIV incidence was high in those reporting some condom use in the past 6 months 
(3·1 per 100 person-years, 2·1–4·3), two or more partners (3·8 per 100 person-years, 2·5–
5·6), or a partner with unknown HIV status (7·0 per 100 person-years, 4·6–10·5). Age, 
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employment status, sexual activity in the past 6 months, number of partners in the past 6 
months, partner’s HIV status, and condom use were included in the multivariable model for 
the men, and partner’s HIV status in the past 6 months emerged as the only significant 
independent predictor of seroconversion for men (table 3). In analyses adjusted for sexual 
activity, number of partners and condom use, all in the past 6 months, as well as age and 
employment, the risk of seroconversion was markedly higher in those men reporting a 
partner who was either HIV positive (HR 2·67, 95% CI 1·06–6·82) or of unknown HIV 
status (4·64, 2·32–9·7, p<0·0001), compared with reporting only HIV-negative partners. 
Reporting an HIV-positive partner accounted for 16% of HIV incidence in men and a partner 
of unknown status 30%, on the basis of the calculated population attributable risk (data not 
shown).
HIV incidence peaked in women in two age strata: 4·3 per 100 person-years (95% CI 3·3–
5·6) in 20–24 year olds and 4·0 per 100 person-years (2·2–7·3) in 35–39 year olds (table 2, 
figure 3). HIV incidence was 4·1 per 100 person-years (3·3–5·0) in unmarried women, 3·7 
per 100 person-years (2·4–5·5) in married women not living with their partner, and 1·4 per 
100 person-years (0·9–2·2) in married women living with their partner. Among women 
reporting sexual risk behaviours or partner characteristics associated with risk, incidence 
was increased: for example, two or more sexual partners in the past 6 months (HIV 
incidence was 10·0 per 100 person-years, 5·0–19·2) or not knowing the HIV status of a 
partner from the past 6 months, (8·0 per 100 person-years, 5·3–12·0).
Age, marital status, sexual activity, condom use, and partner’s HIV status were included in 
the multivariable model for women, and marital status, sexual activity in the past 6 months, 
and partner’s HIV status remained the significant independent predictors of seroconversion 
(table 3). The risk of HIV seroconversion was nearly three times higher in women who 
reported not being married than those who were married (HR 2·90, 95% CI 1·44–5·84, 
p=0·0030) or having a marital partner staying elsewhere than in those who live with their 
partner (2·66, 1·29–5·45, p=0·0078). Not being married or being married with a partner 
living elsewhere accounted for 50% and 25% of HIV incidence among women, respectively 
(data not shown). Reporting no sexual activity at either baseline or follow-up was protective, 
with an HR of 0·22 (95% CI 0·05–0·99, p=0·048). Reporting a partner in the past 6 months 
with HIV-positive status was associated with an increased risk of seroconversion (HR 1·78, 
0·97–3·27, p=0·063); by contrast, reporting a partner with unknown HIV status in the past 6 
months predicted nearly three times the risk of seroconversion compared with reporting only 
HIV-negative partners (HR 2·87, 1·44–5·84, p=0·0030). Reporting any partner with unknown 
HIV status accounted for 16% of HIV incidence (data not shown).
Discussion
The national HIV incidence estimate from SHIMS, a prospective survey of adults in 
Swaziland, on the basis of observed seroconversions was 2·4% in 2011. Modelled estimates 
of HIV seroincidence have ranked Swaziland’s HIV incidence as the highest globally for 
more than a decade, at 4·07% in 2001 and 2·66% in 2009.17,18 Taking into account 
important differences in methods, the 2011 SHIMS estimate is consistent with previous 
modelled estimates, confirming that HIV incidence in Swaziland is alarmingly high but 
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might be stable. Key subsets of the population, including women aged 20–24 years and 35–
39 years and men aged 30–34 years, had incidence rates substantially higher than the 
national rate.
Few characteristics were independent predictors of HIV seroconversion in our study, 
emphasising the homogeneous nature of this generalised epidemic. For women, reporting no 
sexual activity at baseline or follow-up was protective, as might be expected; this predictor, 
however, had only marginal statistical significance. For both women and men, a significant 
predictor of HIV acquisition was reporting a sex partner with unknown HIV status in the 
past 6 months. Although most (89%) of the sexually active, seronegative population of 
adults in Swaziland reported knowing the HIV status of partners they have been with in the 
past 6 months, only 65% of seronegative adults and 71% of the overall adult population in 
Swaziland10 reported any HIV testing before participation in SHIMS. This discrepancy 
between knowledge of partner’s status and the prevalence of reporting prior testing suggests 
it will be crucial to expand HIV testing through a wide range of approaches while 
encouraging HIV disclosure to partners.19 The high population attributable risk observed 
with reporting partners in the past 6 months with unknown HIV status, and for women, 
being unmarried, also suggests the need to consider the use of pre-exposure prophylaxis,20 
expansion of voluntary medical male circumcision, and continued scale-up of treatment as 
prevention, with use of antiretroviral therapy at higher CD4 thresholds.21–23
Key strengths of this study included the systematic sampling of a household-based 
population, a high rate of participation in those sampled, and a high cohort retention rate. 
Although the study did not directly assess the role of migration and migrant labour on the 
epidemic, transient individuals who spent the previous night in someone’s home were 
included in the sampled population. Additionally, having a partner who lives elsewhere, a 
characteristic which might indicate a partner involved in migrant labour, accounted for 25% 
of the HIV incidence in women. A rigorous HIV testing algorithm excluded seronegative 
individuals with acute HIV detected by NAAT testing at enrolment and determined the 
primary endpoint of HIV seroconversion. The number of seroconverters permitted detailed 
assessment of predictors of HIV acquisition. Moreover, Swaziland’s geographic location 
near other high prevalence countries in southern Africa make the results of this study highly 
relevant to the southern Africa region, the centre of the global HIV epidemic.
Study limitations include some imbalance in survey participation, with fewer men and fewer 
younger individuals taking part. The sex bias reflects the greater number of women than men 
in the overall Swaziland population (53% vs 47%1) and higher participation rates by women 
than men in the SHIMS household survey (81% vs 64%10). These sex and age biases, 
however, were reduced by the weighting of the data. Because we did not include injection 
drug use and men who have sex with men behaviours in the model, we were unable to 
quantify the attributable risk of these well known risk behaviours. The survey did not collect 
data for injection drug behaviours, but did collect data on anal sex; however, the non-
response rate for this question was too high to permit inclusion in the proportional hazards 
model. The survey also collected data about the number of partners in the past 6 months, a 
behaviour associated with sex work; this variable was included in the model but was not a 
significant predictor. Because institutionalised individuals whose HIV incidence might be 
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higher or lower than found in SHIMS were not included, the SHIMS estimates of HIV 
incidence might under-represent or over-represent actual HIV incidence.
HIV incidence was defined solely by seroconversion and NAAT testing was not conducted at 
follow-up; this approach might have led to a potential underestimate of overall incidence of 
almost 9% (ie, 2·4% vs 2·6%), assuming a similar number of acute cases at enrolment and 
follow-up. The study was not powered to determine independent predictors of HIV 
seroconversion, and this might explain why some factors previously linked with HIV 
protection or acquisition were not significant predictors of HIV acquisition, such as age in 
women and circumcision in men. Finally, although this was an observational study, risk-
reduction counselling and the provision of condoms during the enrolment phase might have 
altered participants’ risk behaviours and reduced the observed incidence rates below that of 
the rest of the national population.
SHIMS2, a cross-sectional, population-based HIV survey in Swaziland, has recently begun 
(Aug 30, 2016) and will assess the national estimate of HIV incidence after the 2009 
programme expansion. As with other population-based HIV impact assessments,24 the 
cross-sectional design of SHIMS2 will assess HIV incidence by taking advantage of 
advances in HIV incidence assays, namely the limiting antigen avidity assay combined with 
HIV RNA (viral load)7 rather than prospectively observed seroconversions. Results should 
be available by late 2017 and, when available, will show whether the epidemic in Swaziland 
has improved or is much the same. SHIMS2 and population-based HIV impact assessments 
will allow us to understand whether incidence remains the most suitable measure of a 
national HIV epidemic or whether other indicators, such as viral load suppression, will 
emerge as a more informative indicator.
Overall, this study is the first to report HIV incidence at a national level with the use of 
prospectively observed HIV seroconversion. The national HIV incidence in Swaziland of 
2·4% is the highest national rate known. We found alarmingly high rates in men and women 
in specific age strata. In the context of Swaziland’s treatment and male circumcision 
coverage, these high incidence rates warrant further expansion of treatment initiation criteria 
and male circumcision scale-up in Swaziland. Our findings show the value of detailed 
incidence measures in characterising those at highest risk of new infections and emphasise 
the need in high-prevalence countries for evidence-based HIV programmes that include 
frequent HIV testing, support for disclosure of HIV status, expansion of HIV treatment, and 
consideration of pre-exposure prophylaxis as public health priorities.
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Figure 1. 
Distribution of the 575 enumeration areas sampled in the Swaziland HIV Incidence 
Measurement Survey across the four regions of Swaziland
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Figure 2. 
Study flow diagram
SHIMS=Swaziland HIV Incidence Measurement Survey.
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Figure 3. 
HIV incidence by age in Swaziland in 2011
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Table 1
Demographic and behavioural characteristics of HIV-uninfected adults aged 18–49 years in Swaziland in 2011
Total (n=11 232) Men (n=5746) Women (n=5486)
Age (years)*
18–19 1671 (15%) 897 (16%) 774 (14%)
20–24 3330 (30%) 1775 (31%) 1555 (28%)
25–29 2139 (19%) 1207 (21%) 932 (17%)
30–34 1304 (12%) 729 (13%) 575 (10%)
35–39 1041 (9%) 480 (8%) 561 (10%)
40–44 892 (8%) 359 (6%) 533 (10%)
45–49 855 (8%) 299 (5%) 556 (10%)
Residence*
Rural 7897 (70%) 4064 (71%) 3833 (70%)
Urban 3335 (30%) 1682 (29%) 1654 (30%)
Region *
Hhohho 3280 (29%) 1680 (29%) 1600 (29%)
Lubombo 2213 (20%) 1184 (21%) 1029 (19%)
Manzini 3703 (33%) 1874 (33%) 1829 (33%)
Shiselweni 2036 (18%) 1008 (18%) 1028 (19%)
Education*†
Did not attend 563 (5%) 271 (5%) 292 (5%)
Primary 2899 (26%) 1459 (25%) 1440 (26%)
Secondary 5845 (52%) 2945 (51%) 2900 (53%)
Tertiary (any level of education
higher than secondary school)
1877 (17%) 1049 (18%) 828 (15%)
Employment*
Employed 4413 (39%) 2667 (46%) 1746 (32%)
Unemployed, retired, or disabled 5104 (45%) 1971 (34%) 3133 (57%)
Other, refused, or missing 1715 (15%) 1108 (19%) 607 (11%)
Marital status*
Not married 6639 (59%) 3992 (69%) 2647 (48%)
Married, living with partner 2820 (25%) 1200 (21%) 1620 (30%)
Married, partner stays elsewhere 1593 (14%) 494 (9%) 1099 (20%)
Lifetime sexual activity*‡
Never had sex, as reported at 1280 (11%) 885 (15%) 395 (7%)
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Total (n=11 232) Men (n=5746) Women (n=5486)
both baseline and follow-up¶
Ever had sex 9855 (88%) 4788 (83%) 5067 (92%)
Sexual activity within the past 6 months (n=9855; 4788 male, 5067 female)*‡
Sexual activity not reported at
baseline or follow-up
858 (9%) 473 (10%) 385 (8%)
Sexual activity reported at
baseline only
820 (8%) 424 (9%) 396 (8%)
Sexual activity reported at
follow-up only
709 (7%) 449 (9%) 260 (5%)
Sexual activity reported at
baseline and follow-up
7284 (74%) 3333 (70%) 3951 (78%)
Missing 184 (2%) 109 (2%) 75 (2%)
Number of sexual partners in the past 6 months (n=9855; 4788 male, 5067 female)‡
0 1698 (17%) 909 (19%) 789 (16%)
1 7081 (73%) 2946 (62%) 4135 (82%)
≥2 967 (10%) 874 (18%) 93 (2%)
Condom use in the past 6 months (n=8048; 3820 male, 4228 female)‡
Always 2329 (29%) 1317 (35%) 1012 (24%)
Sometimes 2847 (35%) 1416 (37%) 1431 (34%)
Never 2846 (35%) 1073 (28%) 1773 (42%)
HIV status of sexual partners in the past 6 months(n=8048; 3820 male, 4228 female)‡
All negative partners 6160 (77%) 2928 (77%) 3232 (76%)
Any HIV-positive partners 917 (11%) 401 (11%) 516 (12%)
Any partner with unknown
status (and no known
HIV-positive partners)
920 (11%) 466 (12%) 454 (11%)
Male circumcision status*‡
Circumcised at baseline · · 1029 (18%) · ·
Circumcised only at follow-up · · 338 (6%) · ·
Uncircumcised at baseline and
follow-up
· · 4372 (76%) · ·
Current pregnancy status*‡
Pregnant at baseline or
follow-up
· · · · 671 (12%)
Not pregnant at both baseline
and follow-up
· · · · 4802 (88%)
HIV testing history* (n=11 232; 5746 male, 5486 female)
Any previous testing 7330 (65%) 2911 (51%) 4419 (81%)
Lancet HIV. Author manuscript; available in PMC 2017 February 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Justman et al. Page 17
Total (n=11 232) Men (n=5746) Women (n=5486)
No previous testing 3893 (35%) 2830 (49%) 1063 (19%)
Data are survey weighted. Numbers might not add to 100% because of rounding.
*
Indicates data were collected at baseline visit.
†
Education refers to highest level of education ever attended, whether or not that level was completed.
‡
Indicates that data were collected at follow-up visit; unless otherwise indicated, for each variable, 1% or fewer participants refused to answer the 
question, answered “I don’t know”, or had missing data (in these cases data were excluded for the variable).
¶
The variables “lifetime sexual activity” and “recent sexual activity” were constructed from responses to questions at both baseline and follow-up. 
There were 113 people who responded that they had “never had sex” at follow-up but had indicated at the baseline visit that they had been sexually 
active. These individuals were assigned to the category “sexual activity reported at baseline only” within the “recent sexual activity” variable.
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Table 2
Overall HIV incidence and HIV incidence by demographic and behavioural characteristics in Swaziland in 
2011 (n=11 232)
Men Women
Number of
seroconversions
(unweighted)
Number of
seroconversions
(weighted)
Incidence 
per
100 person-
years
(95% CI)*
Number of
seroconversions
(unweighted)
Number of
seroconversions
(weighted)
Incidence per
100 person-
years
(95% CI)*
Overall 47 52·8 1·7 (1·3-2·1) 101 92·5 3·1 (2·6-37)
Age (years)†
 18-19 4 4·0 0·8 (04-1·9) 19 16·0 3·8 (2·6-5·6)
 20-24 15 16·0 1·6 (1·1-2·5) 40 36·4 4·3 (3·3-5·6)
 25-29 14 16·9 2·6 (17-4·0) 12 10·2 2·0 (1·2-3·2)
 30-34 11 12·3 3·1 (1·9-5·1) 9 8·5 2·7 (1·6-4·8)
 35-39 1 1·2 0·4 (0·1-2·2) 10 12·0 4·0 (2·2-7·3)
 40–44 2 24 1·2 (04-3·9) 7 5·8 2·1 (1·1-3·9)
 45-49 0 · · · · 4 3·5 1·2 (0·5-2·7)
Residence†
 Rural 35 38·2 1·7 (1·3-2·2) 76 68·7 3·3 (2·7-4·0)
 Urban 12 14·6 1·6 (1·0-2·6) 25 23·8 2·8 (2·0-3·8)
 Region†
 Hhohho 12 13·9 1·5 (0·9-24) 24 20·5 2·4 (1·7-3·3)
 Lubombo 11 107 1·6 (1·0-2·7) 24 19·3 3·5 (2·5-4·8)
 Manzini 11 13·8 1·4 (0·8-2·3) 32 36·1 37 (2·7-5·0)
 Shiselweni 13 144 2·6 (1·6-4·0) 21 16·6 3·0 (2·1-4·37)
Education†
 Did not attend 2 1·9 1·3 (0·4-4·0) 6 5·2 3·4 (1·7-6·5)
 Primary 16 18·2 2·3 (1·5-3·4) 27 25·3 3·3 (2·4-4·5)
 Secondary 21 23·2 1·4 (1·0-2·1) 63 55·2 3·5 (2·9-4·4)
 Tertiary 8 9·5 1·6 (0·9-2·9) 4 6·0 1·3 (0·5-3·6)
Employment†
 Employed 30 34·9 2·4 (1·8-3·2) 29 26·2 2·8 (2·0-3·8)
 Unemployed, retired, or 
disabled
14 14·8 1·4 (0·9-2·1) 63 58·6 3·5 (2·8-4·5)
 Other, refused, or missing 3 3·0 0·5 (0·2-1·3) 9 7·8 2·4 (1·4-4·2)
Marital status†
 Not married 36 39·1 1·8 (1·4-2·4) 66 58·7 4·1 (3·3-5·0)
 Married, living with 
partner
6 7·5 1·2 (0·6-2·2) 15 12·3 1·4 (0·9-2·2)
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Men Women
Number of
seroconversions
(unweighted)
Number of
seroconversions
(weighted)
Incidence 
per
100 person-
years
(95% CI)*
Number of
seroconversions
(unweighted)
Number of
seroconversions
(weighted)
Incidence per
100 person-
years
(95% CI)*
 Married, partner stays 
elsewhere
5 6·2 2·3 (1·1-4·8) 20 21·5 37 (2·4-5·5)
Lifetime sexual activity†‡
 Never had sex, as reported 
at both
 baseline and follow-up
1 0·8 0·2 (0·0-0·9) 2 1·7 0·8 (0·2-2·4)
 Ever had sex 46 51·9 2·0 (1·6-2·5) 99 90·9 3·3 (2·8-4·0)
Sexual activity within the past 6 months†‡(n=9855)
 Sexual activity not 
reported at baseline or
 at follow-up
0 · · · · 1 1·0 0·5 (0·1-2·4)
 Sexual activity reported at 
baseline only
1 1·8 0·8 (0·2-3·8) 5 3·9 1·8 (0·9, 37)
 Sexual activity reported at 
follow-up only
5 54 2·2 (1·0-4·5) 11 9·1 6·5 (4·0, 10·5)
 Sexual activity reported at 
both baseline
 and follow-up
39 43·6 2·4 (1·8-3·1) 81 76 3·6 (2·9, 4·3)
Number of sexual partners within the past 6 months‡(n=9855)
 0 1 1·8 0·4 (0·1-1·8) 6 4·8 1·1 (0·6-2·2)
 1 29 32·0 2·0 (1·5-2·7) 87 80·8 3·6 (3·0-4·4)
 2 or more 16 18·1 3·8 (2·5-5·6) 6 5·2 10·0 (5·0-19·2)
Condom use in the past 6 months ‡ (in those with one or more partners in the past 6 months)
 Always 11 12·5 1·7 (1·1-2·9) 22 19·4 3·5 (2·5-5·0)
 Sometimes 21 23·3 3·1 (21-43) 39 34·5 4·4 (3·4-5·8)
 Never 13 143 2·5 (1·6-3·9) 31 30·8 3·3 (2·4-4·5)
HIV status of sexual partners in the past 6 months‡ (in those with one or more partners in the past 6 months)
 All HIV-negative partners 20 227 1·4 (1·0-2·0) 54 48·0 2·8 (2·2-3·5)
 Any HIV-positive partners 8 87 4·0 (2·2-7·0) 17 16·3 5·8 (3·9-8·7)
 Any partner with unknown 
status (and no
 known HIV-positive 
partners)
16 18·1 7·0 (4·6-10·5) 20 19·5 8·0 (5·3-12·0)
 Response missing (for all 
partners)
1 0·8 57 (1·1-26·6) 2 2·2 16·7 (5·1-477)
Male circumcision status†‡
 Circumcised at baseline 7 8·4 1·5 (0·8-2·8) · · · · · ·
 Circumcised only at 
follow-up
2 2·2 1·2 (0·4-4·0) · · · · · ·
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Men Women
Number of
seroconversions
(unweighted)
Number of
seroconversions
(weighted)
Incidence 
per
100 person-
years
(95% CI)*
Number of
seroconversions
(unweighted)
Number of
seroconversions
(weighted)
Incidence per
100 person-
years
(95% CI)*
 Uncircumcised at baseline 
and follow-up
37 41·4 1·7 (1·3-2·3) · · · · · ·
Pregnancy status†‡
 Pregnant at baseline or 
follow-up
· · · · · · 16 15·4 4·2 (2·6-6·9)
 Not pregnant at both visits · · · · · · 84 76·1 2·9 (2·4-3·6)
HIV testing history†
 Any previous testing 28 32·6 2·0 (1·5-2·8) 80 74·2 3·1 (2·6-3·8)
 No previous testing 19 202 1·3 (0·9-1·9) 21 18·3 3·2 (2·2-4·6)
Unless otherwise indicated for each variable, 1% or fewer participants refused to answer the question, answered “I don’t know”, or had missing 
data; these data were excluded for the variable.
*
Incidence estimates are based on weighted number of seroconversions.
†
Measured at baseline.
‡
Measured at follow-up visit.
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Table 3
Proportional hazards model of predictors of HIV seroconversion in Swaziland in 2011
Men Women
HR (95% CI) 
for
univariable 
analysis
aHR (95% CI) 
for the
multivariable 
analysis
p value for 
the
multivariable 
analysis
HR (95% CI) 
for
univariable 
analysis
aHR (95% CI) 
for the
multivariable 
analysis
p value for 
the
multivariable 
analysis
Age (years)* p<0·0001 p<0·0001 · · p=0·16 p=0·43 · ·
 18-19 1 1 · · 1 1 · ·
 20-24 1·74 (0·55–543) 0·90 (0·31-2·64) 0·85 1·09 (0·62-1·93) 1·11 (0·59-2·01) 0·76
 25-29 276 (0·88-8·68) 0·82 (0·24-2·77) 0·75 0·53 (0·25-1·12) 0·59 (0·27-1·30) 0·19
 30-34 3·52 (1·09–11·30) 1·10 (0·31-3·84) 0·88 0·76 (0·34-174) 0·89 (0·35-2·26) 0·80
 35-39 0·49 (0·05-4·56) 0·15 (0·02-1·37) 0·092 1·29 (0·55–3·06) 1·58 (0·62-4·01) 0·33
 40–44 1·33 (0·23-7·25) 0·45 (0·08-2·55) 0·37 0·63 (0·26-1·56) 0·90 (0·33–2·45) 0·84
 45-49 · · 0·00 (0·00–0·00) <0·0001 0·41 (0·13-1·23) 0·66 (0·20-2·19) 0·50
Education* p=0·74 · · · · p=0·34 · · · ·
 Did not attend 1 · · · · 1 · · · ·
 Primary 1·71 (0·39-748) · · · · 0·87 (0·35-2·15) · · · ·
 Secondary 1·23 (0·28-5·32) · · · · 0·89 (0·38-2·08) · · · ·
 Tertiary 1·34 (0·28-6·41) · · · · 0·28 (0·06-1·24) · · · ·
Employment* p=0·034 p=0·24 · · p=0·59 · · · ·
 Unemployed, retired, or 
disabled
1 1 · · 1 · · · ·
 Employed 1·77 (0·92-338) 1·59 (0·76-334) 0·22 0·84 (0·53-133) · · · ·
 Other, refused, or missing 0·44 (0·13-1·58) 0·58 (0·16-2·05) 0·40 0·73 (0·35-148) · · · ·
Current marital status* p=0·48 · · · · p=0·0030 p=0·0075 · ·
 Married, living with 
partner
1 · · · · 1 1 · ·
 Married, partner stays 
elsewhere
2·07 (0·62-6·85) · · · · 2·99 (143-5·96) 2·66 (1·29-5·45) 0·0078
 Not married 1·50 (0·63-3·60) · · · · 2·55 (1·44–4·51) 2·90 (1·44–5·84) 0·0030
Sexual activity in the past 6 
months
p<0·0001 p=0·73 · · p<0·0001 p=0·056 · ·
 Sexual activity reported at 
baseline and
 follow-up
1 1 · · 1 1 · ·
 Sexual activity reported at 
baseline only
0·18 (0·02-1·30) 0·62 (0·07-545) 0·66 0·33 (0·14-0·76) 0·46 (0·17-1·25) 0·13
 Sexual activity at follow-
up only
0·7 (0·27-1·79) 0·98 (0·4-2·42) 0·97 1·59 (0·85-3·00) 1·39 (0·71-2·73) 0·34
 Sexual activity not 
reported at baseline or
 at follow-up
0·08 (0·01-0·61) 0·31 (0·04-2·42) 0·26 0·19 (0·05-0·79) 0·22 (0·05-0·99) 0·048
Number of partners in the 
past 6 months (of
p=0·0043 p=0·48 · · p=0·11 · · · ·
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Men Women
HR (95% CI) 
for
univariable 
analysis
aHR (95% CI) 
for the
multivariable 
analysis
p value for 
the
multivariable 
analysis
HR (95% CI) 
for
univariable 
analysis
aHR (95% CI) 
for the
multivariable 
analysis
p value for 
the
multivariable 
analysis
those who ever had sex) †
 1 1 1 · · 1 · · · ·
 2 or more 2·45 (1·32-4·56) 1·27 (0·65-2·48) 0·48 2·01 (0·86-473) · · · ·
Condom use in the past 6 
months†
p=0·0060 p=0·17 · · p=0·028 p=0·71 · ·
 Always 1 1 · · 1 1 · ·
 Sometimes 3·06 (1·49-6·26) 1·91 (0·87-4·19) 0·11 1·89 (1·16-3·05) 1·14 (0·65-2·07) 0·65
 Never 2·70 (1·23-5·91) 2·36 (0·93-5·98) 0·070 1·66 (0·97-2·85) 1·28 (0·71-2·32) 0·40
HIV status of sexual 
partners in the past 6
months (in those with one 
or more partners
in the past 6 months)†
p<0·0001 p<0·0001 · · p<0·0001 p=0·0008 · ·
 All HIV-negative partners 1 1 · · 1 1 · ·
 Any HIV-positive partners 3·93 (173-8·94) 2·67 (1·06-6·82) 0·040 2·48 (1·41-4·37) 1·78 (0·97-3·27) 0·063
 Any partner(s) with 
unknown status
 (with no known HIV-
positive partners)
6·28 (3·27-12·04) 4·64 (2·32-9·27) <0·0001 371 (2·11–6·53) 2·87 (1·44–5·84) 0·0030
Univariable and multivariable models were each analysed separately for men and for women and HR and aHR from the multivariable models are 
shown. Those characteristics that were signifi cant at or near p<0·10 in the univariable model were included in each multivariable model. Not 
shown are those characteristics for which p was greater than 0·10 in the univariable models for men and for women: region, geography (urban vs 
rural), and HIV testing history (any vs never) for men and for women; circumcision status for men; and pregnancy status for women. HR=hazard 
ratio. aHR=adjusted hazard ratio.
*
Measured at baseline visit.
†
Measured at follow-up visit.
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